Nurix Therapeutics, Inc. (NASDAQ:NRIX - Get Free Report) CFO Houte Hans Van sold 1,387 shares of the stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $12.04, for a total transaction of $16,699.48. Following the transaction, the chief financial officer now directly owns 71,832 shares in the company, valued at $864,857.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Houte Hans Van also recently made the following trade(s):
- On Friday, February 16th, Houte Hans Van sold 6,812 shares of Nurix Therapeutics stock. The stock was sold at an average price of $10.02, for a total transaction of $68,256.24.
Nurix Therapeutics Stock Performance
NASDAQ NRIX opened at $12.02 on Wednesday. The company has a market capitalization of $590.80 million, a PE ratio of -4.52 and a beta of 2.06. The company has a 50-day simple moving average of $13.70 and a 200 day simple moving average of $9.83. Nurix Therapeutics, Inc. has a 52-week low of $4.22 and a 52-week high of $18.12.
Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last posted its earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.26). The business had revenue of $15.16 million during the quarter, compared to analysts' expectations of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. As a group, analysts forecast that Nurix Therapeutics, Inc. will post -3.15 EPS for the current fiscal year.
Analysts Set New Price Targets
Everybody laughed when he recommended Netflix
From Stansberry Research | Ad
"This Could be Worth Even More than A.I."
Whitney Tilson's nailed many of the most famous stocks of the last 25 years – including Netflix, Amazon, and Apple. Now he's pounding the table on a new technology rolling out across America, which early estimates say could create more wealth than A.I., the personal computer, and the smartphone combined.
Click here to see how it could become the No. 1 investment of the next decade.
A number of research analysts have weighed in on the stock. Robert W. Baird raised their price objective on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the company an "outperform" rating in a research note on Thursday, April 11th. HC Wainwright dropped their price target on shares of Nurix Therapeutics from $35.00 to $19.00 and set a "buy" rating on the stock in a research report on Tuesday, February 20th. Morgan Stanley raised their price target on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the company an "equal weight" rating in a research report on Monday, February 26th. Royal Bank of Canada raised their price objective on shares of Nurix Therapeutics from $22.00 to $23.00 and gave the stock an "outperform" rating in a report on Thursday, April 11th. Finally, Wells Fargo & Company decreased their price objective on shares of Nurix Therapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Friday, February 16th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $21.33.
Read Our Latest Analysis on Nurix Therapeutics
Hedge Funds Weigh In On Nurix Therapeutics
Large investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. increased its stake in shares of Nurix Therapeutics by 48.1% in the third quarter. Charles Schwab Investment Management Inc. now owns 568,576 shares of the company's stock worth $4,469,000 after purchasing an additional 184,617 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its stake in shares of Nurix Therapeutics by 351.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,611 shares of the company's stock worth $58,000 after purchasing an additional 4,367 shares in the last quarter. Kennedy Capital Management LLC increased its stake in shares of Nurix Therapeutics by 192.7% in the third quarter. Kennedy Capital Management LLC now owns 163,623 shares of the company's stock worth $1,286,000 after purchasing an additional 107,719 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Nurix Therapeutics by 40.9% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 183,923 shares of the company's stock worth $1,446,000 after purchasing an additional 53,429 shares in the last quarter. Finally, ARK Investment Management LLC increased its stake in shares of Nurix Therapeutics by 23.2% in the fourth quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company's stock worth $32,972,000 after purchasing an additional 601,952 shares in the last quarter.
Nurix Therapeutics Company Profile
(
Get Free Report)
Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
